Long-Term Real-World Evaluation of Abrocitinib in Moderate-to-Severe Atopic Dermatitis Across a Diverse Patient Population in a Multi-site Hospital System

Key Points

• Abrocitinib significantly improves symptoms in moderate-to-severe atopic dermatitis patients.
• The analysis included a diverse patient population across multiple sites, reflecting real-world effectiveness.
• Observational assessment across a multi-site hospital system provided insights into long-term outcomes.
• These findings support the need for continued use of abrocitinib in varied clinical settings.